What happened
On October 13, 2026, Aquestive Therapeutics, Inc. (NASDAQ: AQST) said it entered a license agreement with Eton Pharmaceuticals, Inc. for LIBERVANT (diazepam) buccal film.
Eton got exclusive U.S. rights to commercialize the product for seizure clusters, subject to applicable regulatory approvals.
The milestone pool totals up to $47.5 million.
That includes $10.0 million on first U.S. commercial sale, reduced to $5.0 million if full FDA approval for ages 2 to 5 has not been received.
It also includes $2.5 million on FDA approval for ages 6 to 11 and up to $35.0 million tied to annual U.S. sales.
The company will also receive royalties at a mid-teens percentage rate.
The supply agreement makes Aquestive the exclusive manufacturer and supplier. The initial term is 20 years, with automatic three-year renewals unless either side opts out.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| upfront license fee received from Eton | $10.0 million | SEC 8-K | |
| additional regulatory and commercial milestone payments | up to $47.5 million | SEC 8-K | |
| commercial milestones tied to annual U.S. sales | up to $35.0 million | SEC 8-K | |
| initial term of the supply agreement | 20 years | SEC 8-K | |
| U.S. seizure rescue market opportunity | more than $450 million annually | Eton/Aquestive press release |
Read more: Aquestive Therapeutics (AQST) stock analysis and investment case
Why it matters
OptimistFi's case is that the deal strengthens the path from partner revenue to product royalties. It adds upfront cash, milestone potential and a manufacturing role.
The contingent pool is larger than the upfront fee. Up to $35.0 million is tied to annual U.S. sales, and the rest depends on regulatory events.
The press release also says LIBERVANT has orphan-drug designation and patent protection extending into 2038.
In the press release's survey of 101 patients, 71% preferred film and 13% preferred nasal spray, a gap of 58 percentage points.
The key caveat is that the press release says those results reflect stated preferences, not comparative clinical outcomes. The larger payments still depend on future approvals and sales.
Browse: stock research on every company OptimistFi covers
What's next
Eton expects LIBERVANT to be commercially available in April 2027, subject to final FDA approval. The Type 9 NDA has a PDUFA target action date of March 29, 2027.
Approval and launch would support the first-sale milestone and royalties. A delay would push those cash flows out.
More from OptimistFi
- AQST stock: the Aquestive Therapeutics thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — License agreement, upfront fee, milestone terms and supply agreement.
- Eton Pharmaceuticals and Aquestive Therapeutics press release — Launch timing, market opportunity and patient survey results.
Read the full OptimistFi thesis on Aquestive Therapeutics, Inc.: https://optimistfi.com/stocks/AQST
See what would break the Aquestive Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Aquestive Therapeutics, Inc. investment case, its status and the next test to watch live on the Aquestive Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
